

Is it **COVID-19?** The flu? Or something else?

Get answers fast with the
BioFire® Respiratory 2.1 *plus* (RP2.1*plus*) Panel

When “flu season” hits and patients begin to fill waiting rooms, COVID-19 will be everyone’s top suspect. But several respiratory pathogens can cause similar, overlapping symptoms. Now you can test for 23 common respiratory pathogens—including SARS-CoV-2—all with one test and just 45 minutes.

The syndromic approach

Less than 10% of all tests for SARS-CoV-2 in the US have been positive.¹ And even during peak “flu season,” influenza comprised less than one-third of detected respiratory pathogens.²

The CE-marked BioFire RP2.1*plus* Panel uses a syndromic approach, combining the ability to detect 23 common respiratory pathogens into a single, rapid test. Fast answers on a broad range of pathogens may enable the confidence to make targeted treatment decisions; improve patient management regarding admissions, isolations, cohorting, and discharges; and quickly initiate (or discontinue) infection control measures.



BioFire® Respiratory 2.1 *plus* Panel

1 Test. 23 Targets. 45 Minutes.

VIRUSES

Adenovirus
Coronavirus 229E
Coronavirus HKU1
Coronavirus NL63
Coronavirus OC43
Middle East Respiratory
Syndrome Coronavirus (MERS-CoV)
Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2)
Human Metapneumovirus
Human Rhinovirus/Enterovirus

Influenza A
Influenza A/H1
Influenza A/H3
Influenza A/H1-2009
Influenza B
Parainfluenza Virus 1
Parainfluenza Virus 2
Parainfluenza Virus 3
Parainfluenza Virus 4
Respiratory Syncytial Virus

BACTERIA

Bordetella pertussis
Bordetella parapertussis
Chlamydia pneumoniae
Mycoplasma pneumoniae

Overall 97.4% Sensitivity and 99.4% Specificity³

Sample Type: Nasopharyngeal swab in transport media

Don't guess. **Know.**

CE-marked

Product availability varies by country. Consult your bioMérieux representative.

1. The COVID Tracking Project. The Atlantic. Available from: <https://covidtracking.com/data>.

2. BioFire® Syndromic Trends (syndromictrends.com)

3. The stated performance is the aggregate of the prospective data in the BioFire RP2.1*plus* Panel clinical study.



BFR000-9328-01